Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort study
Abstract Background Hematopoietic stem cell transplantation (HSCT) is a standard therapy strategy for most malignant disorders in children. However, transplant-related pneumonia remains a major therapy challenge and mesenchymal stromal cells (MSCs) are rarely reported in HSCT-related pneumonia. The...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-06-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-022-02960-7 |
| _version_ | 1818116909486309376 |
|---|---|
| author | Yuhua Qu Xu Yang Xiaohong Zhang Shanshan Liu Xiaoping Liu Xiaodan Liu Ailing Luo Mansi Cai Yaping Yan Ling Xu Hua Jiang |
| author_facet | Yuhua Qu Xu Yang Xiaohong Zhang Shanshan Liu Xiaoping Liu Xiaodan Liu Ailing Luo Mansi Cai Yaping Yan Ling Xu Hua Jiang |
| author_sort | Yuhua Qu |
| collection | DOAJ |
| description | Abstract Background Hematopoietic stem cell transplantation (HSCT) is a standard therapy strategy for most malignant disorders in children. However, transplant-related pneumonia remains a major therapy challenge and mesenchymal stromal cells (MSCs) are rarely reported in HSCT-related pneumonia. The aim of our study was to assess the efficacy of MSC for HSCT-related pneumonia in children. Methods We retrospectively retrieved HSCT-related (severe and non-severe) pneumonia cases (aged < 18 years), which underwent MSC treatment (MSC group) or non-MSC treatment (non-MSC group) in Guangzhou Women and Children’s Medical Center, from December 2017 to December 2019. We investigated outcomes of the two different treatments among severe cases and non-severe cases, respectively. The primary endpoints were differences in overall cure rate and time to cure between MSC and non-MSC groups. The secondary endpoints were 180-day overall survival and cumulative cure rate. Results Finally, 31 severe pneumonia cases (16 in MSC group, 15 in non-MSC group) and 76 non-severe cases (31 in MSC group, 45 in non-MSC group) were enrolled in this study. Among severe pneumonia cases, overall cure rate in MSC group was significant higher than that in non-MSC group (12[75.0%] vs. 5[33.3%]; OR = 6.00, 95% CI [1.26–28.5]; p = 0.020); the time (days) to cure in MSC group was dramatically reduced compared with that in non-MSC group (36 [19–52] vs. 62 [42–81]; OR = 0.32, 95% CI [0.12–0.88]; p = 0.009); the 180-day overall survival in MSC group was better than that in non-MSC group (74.5% [45.4–89.6] vs. 33.3% [12.2–56.4]; p = 0.013). Among non-severe pneumonia cases, the time (days) to cure in MSC group was notably decreased compared with that in non-MSC group (28 [24–31] vs. 33 [26–39]; OR = 0.31, 95% CI [0.18–0.56]; p = 0.003). Compared with non-MSC group, MSC-treated patients achieved significant improvements of cumulative cure rate not only in severe pneumonia cases (p = 0.027), but also in non-severe cases (p < 0.001). Conclusions This study revealed that MSC treatment could contribute to improving outcomes in children with pneumonia post-HSCT, especially in severe cases. These findings suggest MSC treatment as a promising therapy for HSCT-related pneumonia in children. |
| first_indexed | 2024-12-11T04:30:00Z |
| format | Article |
| id | doaj.art-372cd8f2996144a8bc780d86b5e86387 |
| institution | Directory Open Access Journal |
| issn | 1757-6512 |
| language | English |
| last_indexed | 2024-12-11T04:30:00Z |
| publishDate | 2022-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj.art-372cd8f2996144a8bc780d86b5e863872022-12-22T01:20:54ZengBMCStem Cell Research & Therapy1757-65122022-06-011311910.1186/s13287-022-02960-7Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort studyYuhua Qu0Xu Yang1Xiaohong Zhang2Shanshan Liu3Xiaoping Liu4Xiaodan Liu5Ailing Luo6Mansi Cai7Yaping Yan8Ling Xu9Hua Jiang10Department of Hematology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Hematology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Hematology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Hematology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Hematology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Hematology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Hematology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Hematology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Hematology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Hematology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Hematology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityAbstract Background Hematopoietic stem cell transplantation (HSCT) is a standard therapy strategy for most malignant disorders in children. However, transplant-related pneumonia remains a major therapy challenge and mesenchymal stromal cells (MSCs) are rarely reported in HSCT-related pneumonia. The aim of our study was to assess the efficacy of MSC for HSCT-related pneumonia in children. Methods We retrospectively retrieved HSCT-related (severe and non-severe) pneumonia cases (aged < 18 years), which underwent MSC treatment (MSC group) or non-MSC treatment (non-MSC group) in Guangzhou Women and Children’s Medical Center, from December 2017 to December 2019. We investigated outcomes of the two different treatments among severe cases and non-severe cases, respectively. The primary endpoints were differences in overall cure rate and time to cure between MSC and non-MSC groups. The secondary endpoints were 180-day overall survival and cumulative cure rate. Results Finally, 31 severe pneumonia cases (16 in MSC group, 15 in non-MSC group) and 76 non-severe cases (31 in MSC group, 45 in non-MSC group) were enrolled in this study. Among severe pneumonia cases, overall cure rate in MSC group was significant higher than that in non-MSC group (12[75.0%] vs. 5[33.3%]; OR = 6.00, 95% CI [1.26–28.5]; p = 0.020); the time (days) to cure in MSC group was dramatically reduced compared with that in non-MSC group (36 [19–52] vs. 62 [42–81]; OR = 0.32, 95% CI [0.12–0.88]; p = 0.009); the 180-day overall survival in MSC group was better than that in non-MSC group (74.5% [45.4–89.6] vs. 33.3% [12.2–56.4]; p = 0.013). Among non-severe pneumonia cases, the time (days) to cure in MSC group was notably decreased compared with that in non-MSC group (28 [24–31] vs. 33 [26–39]; OR = 0.31, 95% CI [0.18–0.56]; p = 0.003). Compared with non-MSC group, MSC-treated patients achieved significant improvements of cumulative cure rate not only in severe pneumonia cases (p = 0.027), but also in non-severe cases (p < 0.001). Conclusions This study revealed that MSC treatment could contribute to improving outcomes in children with pneumonia post-HSCT, especially in severe cases. These findings suggest MSC treatment as a promising therapy for HSCT-related pneumonia in children.https://doi.org/10.1186/s13287-022-02960-7Mesenchymal stromal cell (MSC)Hematopoietic stem cell transplantation (HSCT)PneumoniaSevere pneumonia |
| spellingShingle | Yuhua Qu Xu Yang Xiaohong Zhang Shanshan Liu Xiaoping Liu Xiaodan Liu Ailing Luo Mansi Cai Yaping Yan Ling Xu Hua Jiang Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort study Stem Cell Research & Therapy Mesenchymal stromal cell (MSC) Hematopoietic stem cell transplantation (HSCT) Pneumonia Severe pneumonia |
| title | Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort study |
| title_full | Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort study |
| title_fullStr | Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort study |
| title_full_unstemmed | Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort study |
| title_short | Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort study |
| title_sort | mesenchymal stromal cell treatment improves outcomes in children with pneumonia post hematopoietic stem cell transplantation a retrospective cohort study |
| topic | Mesenchymal stromal cell (MSC) Hematopoietic stem cell transplantation (HSCT) Pneumonia Severe pneumonia |
| url | https://doi.org/10.1186/s13287-022-02960-7 |
| work_keys_str_mv | AT yuhuaqu mesenchymalstromalcelltreatmentimprovesoutcomesinchildrenwithpneumoniaposthematopoieticstemcelltransplantationaretrospectivecohortstudy AT xuyang mesenchymalstromalcelltreatmentimprovesoutcomesinchildrenwithpneumoniaposthematopoieticstemcelltransplantationaretrospectivecohortstudy AT xiaohongzhang mesenchymalstromalcelltreatmentimprovesoutcomesinchildrenwithpneumoniaposthematopoieticstemcelltransplantationaretrospectivecohortstudy AT shanshanliu mesenchymalstromalcelltreatmentimprovesoutcomesinchildrenwithpneumoniaposthematopoieticstemcelltransplantationaretrospectivecohortstudy AT xiaopingliu mesenchymalstromalcelltreatmentimprovesoutcomesinchildrenwithpneumoniaposthematopoieticstemcelltransplantationaretrospectivecohortstudy AT xiaodanliu mesenchymalstromalcelltreatmentimprovesoutcomesinchildrenwithpneumoniaposthematopoieticstemcelltransplantationaretrospectivecohortstudy AT ailingluo mesenchymalstromalcelltreatmentimprovesoutcomesinchildrenwithpneumoniaposthematopoieticstemcelltransplantationaretrospectivecohortstudy AT mansicai mesenchymalstromalcelltreatmentimprovesoutcomesinchildrenwithpneumoniaposthematopoieticstemcelltransplantationaretrospectivecohortstudy AT yapingyan mesenchymalstromalcelltreatmentimprovesoutcomesinchildrenwithpneumoniaposthematopoieticstemcelltransplantationaretrospectivecohortstudy AT lingxu mesenchymalstromalcelltreatmentimprovesoutcomesinchildrenwithpneumoniaposthematopoieticstemcelltransplantationaretrospectivecohortstudy AT huajiang mesenchymalstromalcelltreatmentimprovesoutcomesinchildrenwithpneumoniaposthematopoieticstemcelltransplantationaretrospectivecohortstudy |